LENZ THERAPEUTICS, INC.
Income Statement
| Line Item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|---|
| Revenue | — | $19.1M | $0 | — | — | — | — |
| Cost of Revenue | — | $418.0K | $0 | — | — | — | — |
| Gross Profit | — | $18.7M | $0 | — | — | — | — |
| Gross Margin | — | 97.8% | — | — | — | — | — |
| Operating Expenses | |||||||
| Research & Development | — | $18.7M | $29.8M | $59.5M | $72.8M | $37.9M | $9.1M |
| SG&A Expense | — | $91.1M | $28.8M | $12.9M | $32.9M | $22.5M | $4.4M |
| Operating Income | — | $-91.1M | $-58.6M | $-72.4M | $-105.6M | $-60.4M | $-13.5M |
| Operating Margin | — | -477.5% | — | — | — | — | — |
| Interest Expense | — | — | — | — | — | — | — |
| Pretax Income | — | $-81.6M | $-49.8M | $-70.1M | — | — | — |
| Income Tax Expense | — | $502.0K | $1.0K | $-179.0K | $0 | $0 | $0 |
| Net Income | — | $-82.1M | $-49.8M | $-70.0M | $-101.1M | $-70.8M | $-68.4M |
| Net Margin | — | -430.3% | — | — | — | — | — |
| EPS (Basic) | — | $-2.85 | $-2.34 | $-3.25 | $-0.17 | $-0.22 | $-2.72 |
| EPS (Diluted) | — | $-2.85 | $-2.34 | $-3.25 | $-0.17 | $-0.22 | $-2.72 |
| Shares Outstanding (Basic) | 31.4M | 28.8M | 21.3M | 21.6M | 603.6M | 318.1M | 113.1M |
| Shares Outstanding (Diluted) | 31.4M | 28.8M | 21.3M | 21.6M | 603.6M | 318.1M | 113.1M |
| Dividends Per Share | — | — | — | — | — | — | — |